Exenatide extended release and Levemir (Insulin Detemir (Vials))
Determining the interaction of Exenatide extended release and Levemir (Insulin Detemir (Vials)) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using exenatide together with insulin detemir can increase the risk of hypoglycemia, or low blood sugar. You may need a dose adjustment or more frequent monitoring of your blood sugar to safely use both medications. Let your doctor know if you experience hypoglycemia during treatment. Symptoms of hypoglycemia include headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:ADJUST DOSE: Coadministration of a glucagon-like peptide-1 (GLP-1) receptor agonist with insulin may potentiate the risk of hypoglycemia. GLP-1 receptor agonists lower blood glucose by stimulating insulin secretion and lowering glucagon secretion.
MANAGEMENT: When a GLP-1 receptor agonist is used as add-on therapy to basal insulin, a lower dosage of insulin may be required. Blood glucose should be monitored closely, and patients should be counseled to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately and contact their physician. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery. Concurrent use of GLP-1 receptor agonists with prandial insulin has not been studied and is generally not recommended.
- "Product Information. Ozempic (1 mg dose) (semaglutide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
- "Product Information. Adlyxin (lixisenatide)." sanofi-aventis, Bridgewater, NJ.
- "Product Information. Trulicity (dulaglutide)." Eli Lilly and Company, Indianapolis, IN.
- "Product Information. Victoza (liraglutide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
- "Product Information. Tanzeum (albiglutide)." GlaxoSmithKline, Research Triangle Park, NC.
- "Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc, San Diego, CA.
Generic Name: exenatide
Brand name: Byetta Prefilled Pen, Bydureon, Bydureon BCise, Bydureon Pen, Bydureon Tray
Synonyms: Exenatide
Generic Name: insulin detemir
Brand name: Levemir, Levemir FlexPen, Levemir PenFill, Levemir InnoLet, Levemir FlexTouch
Synonyms: Insulin detemir, Insulin Detemir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Exenatide extended release-Levemir FlexPen
- Exenatide extended release-Levemir FlexTouch
- Exenatide extended release-Levetiracetam
- Exenatide extended release-Levetiracetam Extended-Release Tablets
- Exenatide extended release-Levetiracetam Injection
- Exenatide extended release-Levetiracetam Injection, Concentrate
- Levemir (Insulin Detemir (Vials))-Exenatide Extended-Release Injection (Bydureon BCise)
- Levemir (Insulin Detemir (Vials))-Exenatide Extended-Release Injection (Bydureon) (Pens)
- Levemir (Insulin Detemir (Vials))-Exenatide Extended-Release Injection (Bydureon) (Trays)
- Levemir (Insulin Detemir (Vials))-Exenatide Injection (Byetta)
- Levemir (Insulin Detemir (Vials))-Exenatide Subcutaneous
- Levemir (Insulin Detemir (Vials))-Exfoliating Moisturizer